Eisai R&d Management Co., Ltd.

James Palacino

Dominic J Reynolds

Andrew Cook

Ping Zhu

Sudeep Prajapati

Ermira Pazolli

Xiang Liu

Shelby Ellery

Thiwanka Samarakoon

Nathan Elliott Fishkin

Silvia Buonamici

Lihua Yu

Michael W Seiler

Megan Sheehan

Peter G Smith

Yonghong Xiao

Zhenhua Wu

Nicholas Calandra

Jason T Lowe

Shouyong Peng

John JianShi Wang

Guo Zhu Zheng

Ming-Hong Hao

Atsushi Endo

Juan C Almagro

Yoshihiko Kotake

Gregg F Keaney

Kazunobu Kira

Parcharee Tivitmahaisoon

Marta Nevalainen

Cheng Zhong

Norio Murai

Baudouin Gerard

Satoshi Nagao

Masayuki Miyano

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Lisa A Marcaurelle

Ryan Brawn

Ryan Henry

Evan Barry

Morgan Welzel O'shea

Tuoping Luo

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

Anti-BCMA antibody-drug conjugates and methods of use

This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Methods of using splicing modulators

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

Growing community of inventors

Wellesley, MA, United States of America

James Palacino